Modalities to decrease stromal herpes simplex keratitis reactivation rates.
Michael P
MP
Weisberg
Joel
J
Sugar
D000212:Acyclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D000287:Administration, Topical; D000998:Antiviral Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003319:Corneal Stroma / Q000821:virology*; D016572:Cyclosporine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D015352:Dry Eye Syndromes / Q000628:therapy*; D004564:Electrocoagulation / Q000379:methods; D005143:Eyelids / Q000601:surgery; D005938:Glucocorticoids / Q000627:therapeutic use; D018259:Herpesvirus 1, Human / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016849:Keratitis, Herpetic / Q000517:prevention & control* / Q000821:virology; D007765:Lacrimal Apparatus / Q000601:surgery; D055502:Secondary Prevention; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014775:Virus Activation
D000998:Antiviral Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir